NewGen's Cytometry Platform Valued at $19M by Big Four, Poised for Major UAE Expansion
NIVF is trading near its 52-week low of $1.29 (15% above the low).
Summary
NewGenIvf's advanced cytometry platform has received a $19 million valuation from a Big Four accounting firm for its planned UAE/GCC cell sorting business. This valuation is over four times the company's current market capitalization of $4.64 million, indicating significant potential upside. The company is targeting the high-growth IVF market in the UAE/GCC and has appointed Nadeem Malik, a seasoned industry veteran, as Senior Strategic Advisor to spearhead the expansion. This news follows a 6-K filed today announcing the same valuation and comes shortly after the company's 1-for-3 reverse stock split.
At the time of this announcement, NIVF was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.29 to $885.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.